. Author manuscript; available in PMC: 2023 Nov 23.

Published in final edited form as: Cell. 2022 Nov 4;185(24):4541–4559.e23. doi: 10.1016/j.cell.2022.10.012

Table S1.

Genetic crosses and tamoxifen labeling strategy used in this study.

Strategy	Tamoxifen Age	Tamoxifen administration	Tamoxifen Dose (mg)
Rorβ ^CreER ; R26 ^{LSL-synaptophysin-tdTomato}	P21-P25	intraperitoneal injection	5mg (1mg/day)
Kcnip ^CreER ; R26 ^{LSL -ChR2}	P21-P25	intraperitoneal injection	5mg (1mg/day)
PKCγ^CreERT2; Lbx1^FlpO; R26^{LSL-FSF-ReaChR} PKCγ^CreERT2; R26	P21-P25	intraperitoneal injection	5mg (1mg/day)
Ret ^CreERT2 ; Advillin ^FlpO ; R26 ^{LSL-FSF-ReaChR}	E10.5-E11.5	Oral gavage	3mg
Ret ^CreERT2 ; R26 ^{LSL-FSF-ReaChR}	E10.5	Oral gavage	3mg
TrkC ^CreERT2 ; Advillin ^FlpO ; R26 ^{LSL-FSF-ReaChR}	E12.5	Oral gavage	3mg
TrkB ^CreERT2 ; Advillin ^FlpO ; R26 ^{LSL-FSF-ReaChR}	P3	intraperitoneal injection	0.5mg
TrkB ^CreERT2 ; R26 ^LSL-ReaChR	P3	intraperitoneal injection	0.5mg
CGRP ^CreER ; R26 ^LSL-ChR2	P9	intraperitoneal injection	1mg
Mrgprd ^CreERT2 ; R26 ^LSL-ReaChR	P9	intraperitoneal injection	1mg